Home Tags Contrafect

Tag: Contrafect

ContraFect names Michael Messinger CFO

Prior to joining the company in 2012, Messinger was director of finance at Lexicon Pharmaceuticals in Texas.

ContraFect’s CF-301 to enter phase one clinical trials

The Yonkers biotechnology company announces it will begin clinical trials of a treatment for drug-resistant Staph infections.

Investing in Westchester’s biotech surge

Companies like Regeneron and Acorda – and their investors – hope to make a profit, but how does an investor get in on Westchester County’s biotech boom?

ContraFect reports operating loss in Q3

The Yonkers-based biotechnology company releases its third-quarter financial results.

ContraFect hires Bogdanos as general counsel

Natalie Bogdanos joins the Yonkers biotechnology company after holding positions at Memorial Sloan Kettering Cancer Center and Enzo Biochem.

ContraFect announces separation of securities units

Each unit from the Yonkers firm’s initial public offering will separate on Friday into one share of common stock, one Class A warrant and one Class B warrant.

Underwriter of ContraFect IPO buys additional units

Maxim Group L.L.C. exercises its over-allotment option in connection with the biotech company's initial public offering, purchasing 880,333 additional units.

Drug developer exceeds financing target

ContraFect Corp. raises critical financing for clinical stage drug development.

Businesses build a bridge from China to Yonkers

A leading business group in China is a new equity investor in Contrafect Corp. in Yonkers.

Yonkers drug developer ready for first human trials

Contrafect Corp., a Yonkers-based biotechnology company, prepares to begin clinical trials on humans of its first bacteria-killing drug.

Building on biotech in Yonkers

An early-stage biotech company led by an industry pioneer will begin operations this spring in downtown Yonkers.